The bottom line
One of the few longevity-community favorites that is genuinely well-founded: causality is established by genetics and trials, and ApoB meaningfully improves risk assessment over LDL-C, especially in metabolically abnormal people. Not hype. The main gap is that guideline adoption and outcome-defined ApoB targets are still catching up to the mechanistic case.
Mechanism
Every atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a)) carries exactly one ApoB molecule, so ApoB counts the total number of artery-penetrating particles. Because it is the particles, not their variable cholesterol cargo, that get retained in the arterial wall and drive plaque, ApoB is a more direct causal measure of atherosclerotic risk than LDL-C.
What the human evidence shows
Mendelian randomization shows ApoB is causally related to coronary disease and stroke, and reduction of ApoB by any mechanism produces proportional clinical benefit; conversely, lipid therapies that do not lower ApoB have not shown benefit. ApoB and LDL-C are discordant in ~20-60% of people (high triglycerides, obesity, diabetes), and in those cases risk tracks ApoB, so it reclassifies risk missed by standard lipid panels. It is increasingly recommended as a primary target/marker. Whether GLP-1 medicines lower the risk of heart attack and stroke is a separate question from this marker: GLPcompare's page on it, kept by the same team as this review, quotes each label's approved use and sets out the outcome trials.
Typical protocol studied
Serum ApoB; targets vary by risk (roughly <80 mg/dL primary prevention, lower for high risk), used alongside or preferred over LDL-C.
Safety
None (a blood test); does not require fasting.
Key studies
ApoB causally linked to CHD and atherosclerotic stroke subtypes.
PMID: 39758974
ApoB particles and cardiovascular disease (Sniderman narrative review)(2019)
Particle number (ApoB), not cholesterol mass, drives atherogenic risk.
PMID: 30694319 (JAMA Cardiol 2019)